Ex Vivo Mitochondrial Respiration Parallels Biochemical Response to Ibrutinib in CLL Cells

Ex Vivo Mitochondrial Respiration Parallels Biochemical Response to Ibrutinib in CLL Cells

Mitochondrial respiration is becoming more commonly used as a preclinical tool and potential biomarker for chronic lymphocytic leukemia (CLL) and activated B-cell receptor (BCR) signaling. However, respiration parameters have not been evaluated with respect to dose of ibrutinib given in clinical pra...

Full description

Bibliographic Details
Main Authors:	Subir Roy Chowdhury, Cheryl Peltier, Sen Hou, Amandeep Singh, James B. Johnston, Spencer B. Gibson, Aaron Marshall, Versha Banerji
Format:	Article
Language:	English
Published:	MDPI AG 2021-01-01
Series:	Cancers
Subjects:	<b>Keywords: </b>mitochondrial respiration chronic lymphocytic leukemia (CLL) B-cell receptor (BCR) ibrutinib (IB) Bruton tyrosine kinase (BTK) inhibitor plasma chemokine (C-C motif) ligands 3 and 4 (CCL3 and CCL4)
Online Access:	https://www.mdpi.com/2072-6694/13/2/354

Similar Items

Proteolysis Targeting Chimeras for BTK Efficiently Inhibit B-Cell Receptor Signaling and Can Overcome Ibrutinib Resistance in CLL Cells
by: Yamit Shorer Arbel, et al.
Published: (2021-05-01)

Mitochondrial Respiration Correlates with Prognostic Markers in Chronic Lymphocytic Leukemia and Is Normalized by Ibrutinib Treatment
by: Subir Roy Chowdhury, et al.
Published: (2020-03-01)

Ibrutinib in B-cell lymphoma: single fighter might be enough?
by: Chao Xue, et al.
Published: (2020-09-01)

Ibrutinib dose modifications in the management of CLL
by: Camille Hardy-Abeloos, et al.
Published: (2020-06-01)

The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy
by: Ujjani C, et al.
Published: (2020-08-01)

Targeting Bruton Tyrosine Kinase: A novel strategy in the treatment of B-cell lymphomas
by: Sklavenitis-Pistofidis R., et al.
Published: (2017-06-01)

Ibrutinib Could Suppress CA-125 in Ovarian Cancer: A Hypothesis
by: Julian Matthias Metzler, et al.
Published: (2021-12-01)

Die Wirkung des Chemokins "Pulmonary and activation-regulated chemokine" (PARC)auf B-CLL-Zellen und B-Zell-Linien, sowie Untersuchungen zur Expression und Signaltransduktion eines potentiellen PARC-Rezeptors
by: Stadler, Maike
Published: (2010)

The presence of CLL-associated stereotypic B cell receptors in the normal BCR repertoire from healthy individuals increases with age
by: Alice F. Muggen, et al.
Published: (2019-08-01)

Data report on inflammatory C–C chemokines among insulin-using women with diabetes mellitus and breast cancer
by: Zachary A.P. Wintrob, et al.
Published: (2017-04-01)

Bruton's Tyrosine Kinase Inhibition Attenuates the Cardiac Dysfunction Caused by Cecal Ligation and Puncture in Mice
by: Caroline E. O'Riordan, et al.
Published: (2019-09-01)

Acalabrutinib and Its Therapeutic Potential in the Treatment of Chronic Lymphocytic Leukemia: A Short Review on Emerging Data
by: Isaac K, et al.
Published: (2020-03-01)

Btk Inhibitors: A Medicinal Chemistry and Drug Delivery Perspective
by: Chiara Brullo, et al.
Published: (2021-07-01)

Insulin secretagogue use and circulating inflammatory C–C chemokine levels in breast cancer patients
by: Zachary A.P. Wintrob, et al.
Published: (2017-04-01)

Critical molecular pathways in CLL therapy
by: Gerardo Ferrer, et al.
Published: (2018-03-01)

Gene expression pattern of CCL2, CCL3, and CXCL8 in patients with bipolar disorder
by: Mohsen Ghoryani, et al.
Published: (2019-01-01)

Bruton’s Tyrosine Kinase Inhibitors Ibrutinib and Acalabrutinib Counteract Anthracycline Resistance in Cancer Cells Expressing AKR1C3
by: Anselm Morell, et al.
Published: (2020-12-01)

Targeting Bruton’s Tyrosine Kinase in CLL
by: Inhye E. Ahn, et al.
Published: (2021-06-01)

Imbruvica (Ibrutinib) induced subcutaneous hematoma: A case report
by: Chinmay Jani, et al.
Published: (2021-03-01)

Chemokine CCL4 Induced in Mouse Brain Has a Protective Role against Methylmercury Toxicity
by: Tsutomu Takahashi, et al.
Published: (2018-07-01)

Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies
by: Danling Gu, et al.
Published: (2021-03-01)

Spotlight on ibrutinib and its potential in frontline treatment of chronic lymphocytic leukemia
by: Khan M, et al.
Published: (2017-03-01)

Aberrant B Cell Receptor Signaling in Naïve B Cells from Patients with Idiopathic Pulmonary Fibrosis
by: Stefan F. H. Neys, et al.
Published: (2021-05-01)

ACKR4 Recruits GRK3 Prior to β-Arrestins but Can Scavenge Chemokines in the Absence of β-Arrestins
by: Christoph Matti, et al.
Published: (2020-04-01)

Ibrutinib Resistance Is Reduced by an Inhibitor of Fatty Acid Oxidation in Primary CLL Lymphocytes
by: Gabriela Galicia-Vázquez, et al.
Published: (2018-09-01)

The role of ibrutinib in COVID-19 hyperinflammation: A case report
by: Suzanne Maynard, et al.
Published: (2021-04-01)

Successful treatment of “accelerated” chronic lymphocytic leukemia with single agent ibrutinib: A report of two cases.
by: John Xie, et al.
Published: (2021-01-01)

Ibrutinib-induced cardiomyopathy
by: Htay Htay Kyi, et al.
Published: (2019-01-01)

Role of Bruton’s tyrosine kinase in B cells and malignancies
by: Simar Pal Singh, et al.
Published: (2018-02-01)

A review of vaccine effects on women in light of the COVID-19 pandemic
by: Wen-Han Chang
Published: (2020-11-01)

CCR4 Antagonist (C021) Administration Diminishes Hypersensitivity and Enhances the Analgesic Potency of Morphine and Buprenorphine in a Mouse Model of Neuropathic Pain
by: Joanna Bogacka, et al.
Published: (2020-07-01)

Evaluating ibrutinib in the treatment of symptomatic Waldenstrom’s macroglobulinemia
by: Papanota AM, et al.
Published: (2019-08-01)

High expression of Bruton’s tyrosine kinase (BTK) is required for EGFR-induced NF-κB activation and predicts poor prognosis in human glioma
by: Chenglong Yue, et al.
Published: (2017-09-01)

Hide and Seek: The Game Between Chronic Lymphocytic Leukaemia Cells and B Cell Receptor Signalling Inhibitors
by: Kumudha Balakrishnan, et al.
Published: (2017-03-01)

Involvement of Macrophage Inflammatory Protein-1 Family Members in the Development of Diabetic Neuropathy and Their Contribution to Effectiveness of Morphine
by: Ewelina Rojewska, et al.
Published: (2018-03-01)

Overcoming Ibrutinib Resistance in Chronic Lymphocytic Leukemia
by: Bartosz Puła, et al.
Published: (2019-11-01)

Longitudinal CITE-Seq profiling of chronic lymphocytic leukemia during ibrutinib treatment: evolution of leukemic and immune cells at relapse
by: Sarah Cadot, et al.
Published: (2020-12-01)

Dynamic changes of the normal B lymphocyte repertoire in CLL in response to ibrutinib or FCR chemo-immunotherapy
by: Simon Schliffke, et al.
Published: (2018-04-01)

The Role of Novel Agents in Treating CLL-Associated Autoimmune Hemolytic Anemia
by: Alessandro Noto, et al.
Published: (2021-05-01)

Non-Covalent BTK Inhibitors—The New BTKids on the Block for B-Cell Malignancies
by: Katharine L Lewis, et al.
Published: (2021-08-01)